Articolul precedent |
Articolul urmator |
467 2 |
Ultima descărcare din IBN: 2023-10-08 18:00 |
SM ISO690:2012 MORCOV, Cristiana, POGONEA, Ina. Therapeutic management of the migraine. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 26. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 26-26 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. The migraine is a chronic multifactorial pathology, characterized by recurrent headache attacks in subjects with genetic and biological predisposition, affecting 30% of the general population. Successful therapeutic management of the migraine approaches patients individually and multifacetedly. Objective of the study. Identifying the principles of the migraine pharmacotherapy, including interdisciplinary argumentation of the effectiveness of currently approved treatments, based on pathophysiological processes at the CNS level. Material and Methods. A literal review was performed, by selecting and analyzing articles from the HINARI, PubMed and Cochrane Library databases. Results. Recent scientific evidence reveals multiple targets for new medications, these being centered towards the modulation of neural activity, mediated by 5-HT1B, 5-HT1D, 5-HT1F, α1, and CGRP receptors. The mechanisms of action of specific antimigraine drugs result in limiting neuroinflammation and meningeal vasodilation and in reducing the hyperexcitability of the subcortical structures responsible for the migraine symptoms, which are induced by proinflammatory neurotransmitters (CGRP, substance P, neurokininA, etc.). Conclusion. The specific therapeutic management, abortive (ergots, triptans, ditans, gepants, isothiourea’s derivatives) and prophylactic (monoclonal antibodies anti-CGRP / anti-CGRP receptor), demonstrates, according to international and national clinical studies, the efficacy in antimigraine treatment. |
||||||
Cuvinte-cheie migraine, anti-migraine medication, therapeutic management, migrena, preparate antimigrenoase, management terapeutic |
||||||
|